Zepbound vs Mounjaro: Head-to-Head Efficacy Comparison

Same Molecule, Different Label

Zepbound and Mounjaro are tirzepatide. The active pharmaceutical ingredient, the manufacturing process, and the delivery device are identical across both brands. What separates them is the FDA-approved indication printed on the label.

Eli Lilly filed tirzepatide under two separate New Drug Applications (NDAs). The FDA approved Mounjaro in May 2022 as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes. Seventeen months later, the agency approved Zepbound in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

This dual-brand strategy is not unique. Novo Nordisk uses the same approach with semaglutide: Ozempic for diabetes and Wegovy for obesity. The clinical implication is straightforward. A patient's diagnosis determines which brand name appears on the prescription, but the drug entering the body is the same regardless of the box it ships in.

Tirzepatide works as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual-agonist mechanism differentiates it from single-target GLP-1 receptor agonists like semaglutide and liraglutide. GIP receptor activation appears to amplify the appetite-suppressing and insulin-sensitizing effects already produced by GLP-1 receptor engagement.

Why No Head-to-Head Trial Exists

A head-to-head trial between Zepbound and Mounjaro would test tirzepatide against itself. Such a study would generate no useful clinical data because any observed differences would reflect random variation, not pharmacological distinction.

The FDA does not require a manufacturer to run comparative trials between two branded formulations of an identical molecule when both share the same active ingredient, dose strengths, and route of administration. Eli Lilly's prescribing information for both products references the same pharmacokinetic profile: peak plasma concentration at approximately 8 to 72 hours post-injection, a half-life of roughly 5 days, and steady-state achieved after 4 weeks of once-weekly dosing.

The absence of a head-to-head trial is itself evidence. It confirms molecular identity rather than suggesting a gap in the evidence base.

SURMOUNT-1: The Weight-Loss Anchor Trial

The SURMOUNT-1 trial, published in the New England Journal of Medicine in July 2022, enrolled 2,539 adults with obesity or overweight (with at least one comorbidity) who did not have diabetes. Participants were randomized to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo, all administered as weekly subcutaneous injections for 72 weeks.

Results at the 15 mg dose were striking. Mean body-weight loss reached 20.9%, compared with 3.1% for placebo [1]. The 10 mg group achieved 19.5%, and the 5 mg group reached 15.0%. Among participants receiving the 15 mg dose, 36.2% lost ≥25% of their baseline body weight. These figures exceeded those reported in any prior GLP-1 receptor agonist obesity trial at the time of publication.

Adverse events were predominantly gastrointestinal. Nausea occurred in 24.6% of participants at the 15 mg dose versus 9.5% with placebo. Diarrhea rates were 21.0% versus 7.4%. Most GI events were mild to moderate and occurred during the dose-escalation phase, declining after week 20. Discontinuation due to adverse events remained below 7% across all tirzepatide groups [1].

This trial forms the primary efficacy basis for the Zepbound label. Every milligram of tirzepatide used in SURMOUNT-1 is pharmacologically identical to what ships inside a Mounjaro pen.

SURPASS-2: The Diabetes Comparator Trial

The SURPASS-2 trial, published in the New England Journal of Medicine in August 2021, compared tirzepatide head-to-head against semaglutide 1 mg in 1,879 adults with type 2 diabetes already on metformin. This 40-week study randomized participants to tirzepatide 5 mg, 10 mg, or 15 mg, or semaglutide 1 mg.

The primary endpoint was change in A1C from baseline. Tirzepatide 15 mg reduced A1C by 2.30 percentage points, while semaglutide 1 mg achieved a 1.86 percentage-point reduction [2]. All three tirzepatide doses demonstrated superiority to semaglutide 1 mg for A1C reduction and non-inferiority was confirmed at every dose level.

Weight loss favored tirzepatide as well. The 15 mg group lost 12.4 kg versus 6.2 kg for semaglutide 1 mg. That difference, roughly double the weight reduction, attracted considerable attention. It is worth recognizing that SURPASS-2 compared tirzepatide against semaglutide 1 mg (the Ozempic dose), not semaglutide 2.4 mg (the Wegovy dose approved for obesity).

SURPASS-2 data anchor the Mounjaro label. Because the molecule tested was the same tirzepatide now marketed as Zepbound, these diabetes-focused results also inform our understanding of tirzepatide's metabolic effects across indications.

Dose Escalation and Titration: Identical Protocols

Both Zepbound and Mounjaro follow the same dose-escalation schedule. Patients begin at 2.5 mg weekly for 4 weeks. The dose then increases to 5 mg weekly for at least 4 weeks. Subsequent increases occur in 2.5 mg increments every 4 weeks, up to a maximum of 15 mg weekly.

This stepwise approach minimizes gastrointestinal side effects. Data from the SURMOUNT-1 trial showed that nausea and other GI symptoms peaked during escalation and declined substantially once patients stabilized at their maintenance dose [1]. The same pattern appeared in the SURPASS program for diabetes patients.

Both products use Eli Lilly's KwikPen auto-injector. The pen is single-use, pre-filled, and requires no reconstitution. Injection sites include the abdomen, thigh, or upper arm, rotated weekly.

Clinicians sometimes ask whether a patient stable on one brand should "switch" to the other. Pharmacologically, there is nothing to switch. The injection delivers the same compound at the same concentration. What changes is the indication on the prescription and, potentially, the insurance coverage pathway.

Insurance, Cost, and Formulary Differences

While the pharmacology is identical, insurance coverage diverges sharply. This is the single most clinically meaningful difference between the two brands for many patients.

Mounjaro, approved for type 2 diabetes, is covered by most commercial insurance plans and Medicare Part D formularies when prescribed for its on-label indication. Zepbound, approved for obesity, faces a different coverage environment. Medicare currently does not cover anti-obesity medications under Part D, and many commercial plans either exclude weight-management drugs or impose prior authorization with strict BMI and comorbidity requirements.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends tirzepatide as a first-line pharmacotherapy option for adults with BMI ≥30 or BMI ≥27 with weight-related complications. This guideline endorsement may influence future payer coverage decisions, but it has not yet resolved the gap between diabetes and obesity formulary access.

List price for both products is approximately $1,060 per month without insurance, though manufacturer savings programs and prior authorization pathways can reduce out-of-pocket costs substantially. Patients with type 2 diabetes and obesity may find that a Mounjaro prescription written for the diabetes indication provides better insurance coverage while delivering the same weight-loss benefits documented in the SURMOUNT trials.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has noted: "The distinction between treating obesity and treating diabetes with the same molecule reflects regulatory and insurance frameworks, not differences in the medicine itself."

Efficacy Across Populations: What the Broader SURMOUNT and SURPASS Programs Show

The SURMOUNT program extends beyond its first trial. SURMOUNT-2 enrolled adults with obesity and type 2 diabetes, demonstrating 14.7% mean weight loss at 15 mg over 72 weeks versus 3.2% for placebo [3]. This trial bridged the gap between the weight-management and diabetes programs, confirming that tirzepatide produces substantial weight loss even in patients with T2D, a population historically harder to treat with anti-obesity medications.

SURMOUNT-3 and SURMOUNT-4 examined tirzepatide after an initial lifestyle intervention run-in period and a withdrawal-randomization design, respectively. Results confirmed that continued tirzepatide treatment is necessary to maintain weight loss and that stopping the drug leads to significant regain [4].

On the diabetes side, SURPASS-1 studied tirzepatide as monotherapy in treatment-naive T2D patients, while SURPASS-3 compared it against insulin degludec. SURPASS-4, a 104-week cardiovascular outcomes-focused trial, showed an A1C reduction of 2.58 percentage points at 15 mg, the largest observed across the program [5].

These results all describe the same drug. A clinician reviewing SURMOUNT data for a Zepbound patient and SURPASS data for a Mounjaro patient is reading about the same molecule's performance in different populations.

Safety Profile: One Drug, One Risk Assessment

Because Zepbound and Mounjaro deliver the same compound, their safety profiles are identical. The FDA prescribing information for both products carries the same boxed warning regarding thyroid C-cell tumors observed in rodent studies with GLP-1 receptor agonists.

Common adverse reactions across both labels include nausea (12% to 18% at maintenance doses), diarrhea (12% to 17%), decreased appetite (5% to 11%), vomiting (5% to 9%), constipation (5% to 7%), dyspepsia, and injection-site reactions. The incidence of pancreatitis across the combined SURMOUNT and SURPASS programs was <0.2%, consistent with rates observed with other incretin-based therapies [1][2].

Both labels carry contraindications for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Gallbladder-related events, including cholelithiasis and cholecystitis, occurred at higher rates in tirzepatide-treated patients than placebo across the SURMOUNT trials, consistent with rapid weight loss as an independent risk factor for gallstone formation.

A patient who experiences an adverse event on Mounjaro will experience the same event on Zepbound at the same dose. There is no pharmacological rationale for switching brands to manage side effects.

When Clinicians Choose One Label Over the Other

The prescribing decision between Zepbound and Mounjaro rests on diagnosis, not drug preference. An endocrinologist treating a patient with type 2 diabetes prescribes Mounjaro. An obesity medicine specialist treating a patient with BMI ≥30 and no diabetes prescribes Zepbound.

The more complex clinical scenario arises with patients who have both conditions. A patient with T2D and obesity could receive either brand. In practice, clinicians typically choose the label that maximizes insurance coverage. For patients with a primary diabetes diagnosis, Mounjaro often provides a smoother prior-authorization pathway.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on obesity management recommends selecting anti-obesity pharmacotherapy based on magnitude of weight loss needed, comorbidity profile, and insurance access. AACE explicitly acknowledges that formulary constraints often drive brand selection when the same molecule is available under multiple trade names.

Dr. W. Timothy Garvey, Professor of Medicine at the University of Alabama at Birmingham and a lead SURMOUNT investigator, stated: "Tirzepatide is tirzepatide. The clinical outcomes we observed in SURMOUNT-1 reflect the molecule's biology, not the brand name on the pen."

What Matters for Patients Considering Tirzepatide

For patients evaluating their options, the comparison between Zepbound and Mounjaro reduces to three practical questions. First: what is your primary diagnosis? This determines which brand your clinician will prescribe. Second: what does your insurance cover? This determines your out-of-pocket cost. Third: are you at the right dose? The efficacy differences that matter are between 5 mg, 10 mg, and 15 mg dosing, not between brand names.

Patients should not interpret the existence of two brand names as evidence of two different drugs. The dual-brand structure exists because the FDA requires separate regulatory approvals for distinct therapeutic indications, and because obesity and diabetes carry different diagnostic codes, coverage policies, and prescribing contexts.

A patient receiving tirzepatide 15 mg weekly, whether from a Zepbound pen or a Mounjaro pen, can expect the same pharmacokinetic profile, the same receptor-binding activity, the same clinical outcomes documented across the SURMOUNT and SURPASS programs, and the same side-effect risk. The 20.9% mean weight loss observed in SURMOUNT-1 at 72 weeks [1] belongs to tirzepatide as a molecule, not to either brand exclusively.